CPHI Milan 2026: AI and Bioavailability, Part 2

As part of PharmTech’s coverage of CPHI Milan, Andrew Parker, PhD, executive drug development consultant, Quotient Sciences, discusses about how artificial intelligence (AI) is being integrated into pharmaceutical formulation development.

Parker believes that AI adoption in formulation science is still in the early stages, with formulators still deciding how the technology can be used most effectively. AI is not replacing workers, assures Parker, but rather enhancing their ideas and helping to catalyze development within the constraints of a given formulation program. He stressed that human-in-the-loop evaluation remains essential, but AI may enable more efficient programs and help teams meet target profiles faster.

Flexibility built around adaptive dose titration is key. Parker explained that when a new therapeutic's solubility and bioavailability in humans aren’t yet well understood, Quotient Sciences’ Translational Pharmaceutics platform allows teams to avoid locking in dose strengths prematurely, deferring that decision until after the first human study. This de-risks development by not forcing commitments based on incomplete data.

He also emphasized the importance of horizontal integration between chemistry/CMC teams and clinical development teams. Rather than defaulting to commercially viable, long-shelf-life formulations, teams should ask what’s truly needed at each development stage to avoid wasting time, money, and effort generating redundant data for formulations that will never be used beyond an early-phase study.

Quotient Sciences can be found at Booth 6K73 at CPHI Milan, which is occurring from October 6-8, 2026.

Click the video above to watch part 2 of this 2-part interview.

Click here to watch part 1.